Y Intercept Hong Kong Ltd increased its stake in Genmab A/S (NASDAQ:GMAB - Free Report) by 371.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 73,696 shares of the company's stock after purchasing an additional 58,048 shares during the period. Y Intercept Hong Kong Ltd's holdings in Genmab A/S were worth $1,538,000 as of its most recent SEC filing.
Several other institutional investors also recently modified their holdings of the stock. Two Sigma Advisers LP increased its position in shares of Genmab A/S by 84.1% in the third quarter. Two Sigma Advisers LP now owns 615,100 shares of the company's stock worth $14,996,000 after purchasing an additional 280,900 shares during the last quarter. FMR LLC increased its position in shares of Genmab A/S by 13.5% in the third quarter. FMR LLC now owns 278,194 shares of the company's stock worth $6,782,000 after purchasing an additional 33,076 shares during the last quarter. Oppenheimer Asset Management Inc. increased its position in shares of Genmab A/S by 6.5% in the third quarter. Oppenheimer Asset Management Inc. now owns 232,243 shares of the company's stock worth $5,662,000 after purchasing an additional 14,165 shares during the last quarter. Natixis Advisors LLC boosted its stake in Genmab A/S by 29.8% in the third quarter. Natixis Advisors LLC now owns 206,563 shares of the company's stock worth $5,036,000 after buying an additional 47,437 shares in the last quarter. Finally, ABC Arbitrage SA purchased a new stake in Genmab A/S in the fourth quarter worth approximately $3,692,000. 7.07% of the stock is currently owned by institutional investors.
NASDAQ:GMAB opened at $22.96 on Wednesday. The firm has a market cap of $15.19 billion, a PE ratio of 13.20, a price-to-earnings-growth ratio of 2.65 and a beta of 0.96. Genmab A/S has a fifty-two week low of $18.64 and a fifty-two week high of $31.88. The business has a 50 day moving average price of $20.83 and a 200-day moving average price of $22.84.
Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its earnings results on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, beating analysts' consensus estimates of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. Research analysts predict that Genmab A/S will post 1.45 EPS for the current year.
Several analysts have issued reports on GMAB shares. BMO Capital Markets reaffirmed an "outperform" rating and issued a $48.00 target price (up previously from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. Sanford C. Bernstein raised Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Friday, December 20th. HC Wainwright reaffirmed a "buy" rating and issued a $50.00 target price on shares of Genmab A/S in a research note on Thursday, January 23rd. BNP Paribas raised Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Tuesday, February 11th. Finally, Leerink Partners raised Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 target price for the company in a research note on Thursday, February 13th. Four equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $42.17.
Read Our Latest Stock Report on GMAB
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.